Temsirolimus with or without Megestrol Acetate and Tamoxifen for Endometrial Cancer: a Gynecologic Oncology Group Study

BACKGROUND: Preclinical evidence suggested that blockade of the PI3K/AKT/mTOR pathway might overcome resistance to hormonal therapy. METHODS: We performed a randomized phase II trial of intravenous temsirolimus 25 mg weekly versus the combination of weekly temsirolimus with a regimen of megestrol ac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fleming, Gini F., Filiaci, Virginia L., Marzullo, Brandon, Zaino, Richard J., Davidson, Susan A., Pearl, Michael, Makker, Vicky, Burke, James J., Zweizig, Susan L., Van Le, Linda, Hanjani, Parviz, Downey, Gordon, Walker, Joan L., Reyes, Henry D., Leslie, Kimberly K.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063288/
https://ncbi.nlm.nih.gov/pubmed/24456823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.01.015
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars